Cardiac remodeling includes changes to both cardiomyocytes and cardiac fibroblasts as well as vascular smooth muscle cells (VSMCs) and perivascular fibroblasts of intracoronary arteries which occur in response to injury to the heart concomitant with hypertension, myocardial infarction, or aging. These alterations, due to both hemodynamic and humoral factors such as angiotensin II (Ang II) and endothelin (Et-1), result in left ventricular hypertrophy, coronary artery thickening as well as perivascular and interstitial fibrosis. Angiotensin- (1-7) [Ang-(1-7)] is an anti-proliferative and anti-fibrotic peptide which opposes the mitogenic, pro-fibrotic effects of various mitogens and hormones including Ang II. During the current funding cycle of Project 2, we showed that Ang-(1-7) inhibits the growth of cardiac myocytes through activation of the G protein-coupled receptor mas and inhibition of the phosphorylation/activation of the mitogen-activated protein (MAP) kinases ERK1 and ERK2. The heptapeptide reduces proliferation and decreases collagen synthesis in cardiac fibroblasts, concomitant with up-regulation of the MAP kinase phosphatase DUSP1 and down-regulation of cyclooxygenase-2 (COX-2) and prostaglandin E synthase (PGES-1). Ang-(1-7) also increases DUSP1 in VSMCs, to attenuate ERK1/ERK2 activities, inhibit VSMC growth, and reduce vascular hypertrophy and perivascular fibrosis. Based upon these observations, the hypothesis of this project is that Ang-(1-7) counterregulates the effects of Ang II by up-regulating the MAP kinase phosphatase DUSP1 to prevent hypertrophy and reduce fibrosis. Preliminary studies show that administration of Ang-(1-7) to normotensive rats chronically treated with Ang II causes a pressure-independent reduction in the interstitial and perivascular fibrosis and coronary artery hypertrophy associated with cardiac remodeling. We will use this model to identify the molecular mechanisms by which Ang-(1-7) inhibits cell growth and fibrosis, using a combination of molecular biology, proteonomic and immunocytochemical techniques. The role of the protein phosphatase DUSP1 in hypertrophy and fibrosis will be studied in normotensive rats transfected with lentivirus containing shRNAs to the MAP kinase phosphatase DUSP1 to reduce or ablate the enzyme in vivo and attenuate the response to Ang-(1-7) treatment. The role of Ang-(1-7) in preventing the Ang ll-mediated inflammatory response by reducing cyclooxygenase 2 (COX-2) activity or prostaglandin synthase activities to alter the ratio of proliferative to anti-proliferative prostanoids will be determined in vitro and in vivo, in cultured cells and tissues from rats treated with angiotensin peptides. Finally, hypertensive rats of the mRen2.Lewis congenic strain, normotensive rats with ischemia/reperfusion injury and aged rats with progressive heart disease will be treated with Ang-(1-7), in preclinical studies to demonstrate the efficacy of Ang-(1-7) in reducing cardiac hypertrophy and fibrosis. Ang-(1-7) may represent a novel targeted therapeutic treatment for cardiac pathologies associated with high blood pressure, myocardial infarction, and aging.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL051952-19
Application #
8378039
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2012-04-01
Budget End
2013-03-31
Support Year
19
Fiscal Year
2012
Total Cost
$261,761
Indirect Cost
$84,896
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Wang, Hao; Sun, Xuming; Chou, Jeff et al. (2017) Inflammatory and mitochondrial gene expression data in GPER-deficient cardiomyocytes from male and female mice. Data Brief 10:465-473
Ferrario, Carlos M; Mullick, Adam E (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacol Res 125:57-71
Chappell, Mark C; Al Zayadneh, Ebaa M (2017) Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways. J Cell Signal 2:
Brosnihan, K Bridget; Chappell, Mark C (2017) Measurement of Angiotensin Peptides: HPLC-RIA. Methods Mol Biol 1527:81-99
Wang, Hao; Sun, Xuming; Chou, Jeff et al. (2017) Cardiomyocyte-specific deletion of the G protein-coupled estrogen receptor (GPER) leads to left ventricular dysfunction and adverse remodeling: A sex-specific gene profiling analysis. Biochim Biophys Acta 1863:1870-1882
Butts, Brittany; Goeddel, Lee A; George, David J et al. (2017) Increased Inflammation in Pericardial Fluid Persists 48 Hours After Cardiac Surgery. Circulation 136:2284-2286
Alencar, Allan K; da Silva, Jaqueline S; Lin, Marina et al. (2017) Effect of Age, Estrogen Status, and Late-Life GPER Activation on Cardiac Structure and Function in the Fischer344√óBrown Norway Female Rat. J Gerontol A Biol Sci Med Sci 72:152-162
Ahmad, Sarfaraz; Varagic, Jasmina; VonCannon, Jessica L et al. (2016) Primacy of cardiac chymase over angiotensin converting enzyme as an angiotensin-(1-12) metabolizing enzyme. Biochem Biophys Res Commun 478:559-64
Fu, Lianwu; Wei, Chih-Chang; Powell, Pamela C et al. (2016) Increased fibroblast chymase production mediates procollagen autophagic digestion in volume overload. J Mol Cell Cardiol 92:1-9
Thapa, Narendra; Tan, Xiaojun; Choi, Suyong et al. (2016) The Hidden Conundrum of Phosphoinositide Signaling in Cancer. Trends Cancer 2:378-390

Showing the most recent 10 out of 296 publications